$69.2 2.0 2.9%
Last Trade - 05/03/21
| Market Cap | £2.19bn |
| Enterprise Value | £2.15bn |
| Revenue | £310.4m |
| Position in Universe | 1806th / 6651 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 249 | 276.4 | 286.6 | 337.3 | 421 | 429.6 | 535.8 | 621.5 | +11.5% | ||
| +872.1 | +2,724 | -4.51 | +22.9 | |||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | December 22, 2006 |
| Public Since | February 3, 2011 |
| No. of Shareholders: | 12 |
| No. of Employees: | 624 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Nasdaq Composite , S&P 600 Small Cap , S&P Composite 1500 , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 43,863,467 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 5 Sylvan Way Ste 300, PARSIPPANY, 07054-3813, United States |
| Web | http://www.pacira.com/ |
| Phone | +1 973 2543560 |
| Contact | Susan Mesco (IR Contact Officer) |
| Auditors | KPMG LLP |
As of 05/03/21, shares in Pacira Biosciences Inc are trading at $69.2, giving the company a market capitalisation of £2.19bn. This share price information is delayed by 15 minutes.
Shares in Pacira Biosciences Inc are currently trading at $69.2 and the price has moved by 67.51% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pacira Biosciences Inc price has moved by 32.13% over the past year.
Of the analysts with advisory recommendations for Pacira Biosciences Inc, there are there are currently 2 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Pacira Biosciences Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Pacira Biosciences Inc is scheduled to issue upcoming financial results on the following dates:
Pacira Biosciences Inc does not currently pay a dividend.
Pacira Biosciences Inc does not currently pay a dividend.
Pacira Biosciences Inc does not currently pay a dividend.
To buy shares in Pacira Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Pacira Biosciences Inc are currently trading at $69.2, giving the company a market capitalisation of £2.19bn.
Here are the trading details for Pacira Biosciences Inc:
Based on an overall assessment of its quality, value and momentum, Pacira Biosciences Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Pacira Biosciences Inc are currently priced at $69.2. At that level they are trading at 6.82% discount to the analyst consensus target price of 0.00.
Analysts covering Pacira Biosciences Inc currently have a consensus Earnings Per Share (EPS) forecast of 3.497 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacira Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been 1.11%. At the current price of $69.2, shares in Pacira Biosciences Inc are trading at 16.56% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pacira Biosciences Inc PE ratio based on its reported earnings over the past 12 months is 18.9. The shares are currently trading at $69.2.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pacira Biosciences Inc's management team is headed by:
Here are the top five shareholders of Pacira Biosciences Inc based on the size of their shareholding:
